CORVEL CORPORATION

CRVL

CIK 0000874866 · Quarterly mode · latest period FY2025 (Q4) (ending 2025-12-31) · sourced from SEC EDGAR

At a glance · FY2025 (Q4)

Revenue
$236M
↑+3.4% +$8Mvs FY2024 (Q4)
Operating Income
$47M
↑+3.3% +$1Mvs FY2024 (Q4)
Net Income
$24M
↑+1.7% +$403Kvs FY2024 (Q4)
Gross Profit
$55M
↑+3.9% +$2Mvs FY2024 (Q4)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Weak
33/100
  • Profitability
    0Insufficient data
  • Liquidity
    70Current Ratio 1.90 (above 1.5 = solid)
  • Leverage
    0Insufficient data
  • Efficiency
    100Asset Turnover 1.79x (1.0+ = capital-efficient)
  • Growth
    28Revenue YoY +3.4% (10% = solid, 25%+ = elite)
  • Margin Trend
    0Insufficient data

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

DCF intrinsic value

DCF intrinsic value

two-stage Gordon model

Project CRVL's free cash flow forward, discount back at your hurdle rate, divide by diluted shares. Edit the assumptions to see how sensitive the intrinsic value is.

25%

Trailing 3-yr CAGR was 34.8%

10%

10% is a common all-equity benchmark for US large-caps

2.5%

Should be ≤ long-run GDP growth (~2.5% nominal)

5

5-year explicit projection + perpetuity terminal

Intrinsic value per share
$58.74
Total enterprise IV
$3.05B
Diluted shares
0.05B
Terminal PV
$2.37B (78% of total)
Year-5 FCF
$279M
YearProjected FCFDiscounted PV
+1$114M$104M
+2$143M$118M
+3$179M$134M
+4$224M$153M
+5$279M$173M
Terminal$3.82B$2.37B

DCF outputs are HIGHLY sensitive to growth + WACC assumptions. A 1pp WACC change can shift IV by 20%+. Use this as a sanity-check vs market price, not a target — and always cross-check the underlying FCF source (EDGAR cashflow statement, latest annual). Margin of safety convention: 30-50% discount to IV before buying.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
$45M
investment in PP&E
Stock buybacks (TTM)
$45M
share count reduction
Stock-based comp (TTM)
$6M
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$645M
everything owned
Total liabilities
$269M
everything owed
Stockholders' equity
$376M
shareholder claim

Recent performance · 63 quarters

Revenue↑+3.4% +$8M
$236M
Net Income↑+1.7% +$403K
$24M
Free Cash Flow↑+9.5% +$3M
$35M

Drill down